Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.

导出 OA

翻译打印收藏纠错

作者： Roberto,Moretto ^[1] ; Chiara,Cremolini ^[1] ; Daniele,Rossini ^[1] ; Filippo,Pietrantonio ^[2] ; Francesca,Battaglin ^[3] ; Alessia,Mennitto ^[2] ; Francesca,Bergamo ^[3] ; Fotios,Loupakis ^[1] ; Federica,Marmorino ^[1] ; Rosa,Berenato ^[2] ; Valentina Angela,Marsico ^[3] ; Marta,Caporale ^[2] ; Carlotta,Antoniotti ^[1] ; Gianluca,Masi ^[1] ; Lisa,Salvatore ^[1] ; Beatrice,Borelli ^[1] ; Gabriella,Fontanini ^[4] ; Sara,Lonardi ^[3] ; Filippo,De Braud ^[2] ; Alfredo,Falcone ^[5]

作者单位： Polo Oncologico, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy University of Pisa, Pisa, Italy. ^[1] Medical Oncology Department, Fondazione Istituti di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy. ^[2] Unit of Medical Oncology 1, Istituto Oncologico Veneto, Istituti di Ricovero e Cura a Carattere Scientifico, Padua, Italy. ^[3] Division of Pathology, Department of Surgical, Medical, Molecular Pathology, and Critical Area, University of Pisa, Pisa, Italy. ^[4] Polo Oncologico, Azienda Ospedaliero-Universitaria Pisana, Istituto Toscano Tumori, Pisa, Italy University of Pisa, Pisa, Italy alfredo.falcone@med.unipi.it. ^[5]

关键词 Anti-EGFR monoclonal antibodies Left-sided tumor Metastatic colorectal cancer Right-sided tumor